Deepbridge are pleased to announce the appointment of Dr Andy Round, as Senior Investment Director, within the Deepbridge Life Sciences EIS team. 

This recruitment forms part of Deepbridge’s wider restructuring programme, following the promotion of Ben Carter to Head of Life Sciences and the additions of Simon Thelwall-Jones, David Blake and Oliver Wheatley to Deepbridge’s Tech Investment Team; with Dr Savvas Neophytou as Chief Investment Officer. 

With over £230m invested to date and over 75% of investment being outside of London, Deepbridge is one of the most active regional early-stage investors in the UK; reporting a record year of fundraising during the 2021/22 tax year, supporting investee companies within the Deepbridge Technology Growth EIS and Deepbridge Life Sciences EIS funds. 

Ian Warwick, Managing Partner at  Deepbridge Capital, commented: 

“My colleagues and I have known Andy for many years, having co-invested with Andy on numerous occasions, so we are delighted that he has now joined Deepbridge; which is testament to the quality of the life sciences companies in our portfolio." 

Ben Carter, Head of Life Sciences at Deepbridge Capital, added: 

“Our objective within the Deepbridge Life Sciences Investment Team is to identify, select and proactively support the very best early-stage life sciences opportunities across the UK. Andy’s domain expertise and wealth of experience will be an invaluable addition to our team as we seek to grow the great medtech, pharma, biotech and digital healthcare companies of tomorrow.” 

Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).